{"entity":{"id":"leukaemia-type","kind":"term","name":"Leukaemia (tissue type)","aka":["leukaemias","leukemia","leukemias","leukemic","leukaemic","blood cancer","blood cancers","haematological malignancy","haematological malignancies","hematologic malignancy","hematologic malignancies","haematological cancer","haematological cancers","liquid tumour","liquid tumours","acute leukaemia","chronic leukaemia","acute leukaemias","haematologic malignancies","haematologic malignancy"],"tldr":"Cancer of the blood-forming cells in the bone marrow, which flood the blood with immature or abnormal white cells and crowd out normal blood production. It has no single lump to remove.","summary":"Leukaemias are classed as acute (fast, immature cells, needs urgent treatment) or chronic (slow, more mature cells), and as myeloid or lymphoid by the cell lineage: AML, ALL, CML and CLL. Because leukaemia cells are accessible in blood and marrow, they were the first cancers to be treated with combination chemotherapy (childhood ALL, 1960s), the first with a targeted drug (imatinib for CML, 2001), the first with CAR-T (ALL, 2017), and the first where measuring residual disease guided therapy. Along with lymphomas and myeloma they form the haematological malignancies, which make up roughly a tenth of all cancers.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Leukemia","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Leukemia"}],"tags":[],"related":["lymphoma-type","bone-marrow","stem-cell","mrd","carcinoma"],"cancers":["aml","all-leukemia","cll","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["imatinib","venetoclax","blinatumomab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Biology basics"},"route":"/terms/leukaemia-type/","neighbours":{"term":[{"id":"b-cell","kind":"term","name":"B cell","route":"/terms/b-cell/"},{"id":"bone-marrow","kind":"term","name":"Bone marrow","route":"/terms/bone-marrow/"},{"id":"carcinoma","kind":"term","name":"Carcinoma","route":"/terms/carcinoma/"},{"id":"lymphoma-type","kind":"term","name":"Lymphoma (tissue type)","route":"/terms/lymphoma-type/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"stem-cell","kind":"term","name":"Stem cell","route":"/terms/stem-cell/"}],"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"plasma-cell-leukaemia","kind":"cancer","name":"Plasma cell leukaemia","route":"/cancers/plasma-cell-leukaemia/"}],"drug":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"},{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"person":[{"id":"marco-herold","kind":"person","name":"Marco Herold","route":"/people/marco-herold/"},{"id":"robert-negrin","kind":"person","name":"Robert Negrin","route":"/people/robert-negrin/"}],"journal":[{"id":"clinical-advances-in-hematology-and-oncology","kind":"journal","name":"Clinical advances in hematology & oncology","route":"/journals/clinical-advances-in-hematology-and-oncology/"},{"id":"leukemia","kind":"journal","name":"Leukemia","route":"/journals/leukemia/"},{"id":"oncology-williston-park","kind":"journal","name":"Oncology (Williston Park)","route":"/journals/oncology-williston-park/"}]}}